Published date: 12 February 2021
Last edited date: 28 October 2021
Awarded contract - This means that the contract has been awarded to a supplier.
Contract summary
Industry
Vaccines - 33651600
Location of contract
United Kingdom
Value of contract
£1
Procurement reference
4846/01/2021
Published date
12 February 2021
Closing date
14 January 2021
Closing time
11:59pm
Contract start date
15 January 2021
Contract end date
31 December 2021
Contract type
Supply contract
Procedure type
Single tender action (below threshold)
A direct contract with a single supplier, without competition.
This procedure can be used for procurements below the relevant contract value threshold.
Contract is suitable for SMEs?
No
Contract is suitable for VCSEs?
No
Description
Procurement of Janssen's vaccine candidate Ad26.COV2-S.
Award information
Awarded date
15 January 2021
Contract start date
15 January 2021
Contract end date
31 December 2021
Total value of contract
£1
This contract was awarded to 1 supplier.
JANSSEN PHARMACEUTICA NV
Address
30 Turnhoutseweg
B-2340 Beerse
BelgiumReference
No reference - other
Value of contract
£1
Supplier is SME?
No
Supplier is VCSE?
No
Attachments
-
- ADVANCE PURCHASE AGREEMENT - [REDACTED].pdf
- Signed contract
Additional details
-
Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors .
Contract end date is being withheld on grounds that release of the information would be contrary to public interest under Regulation 50(6)(a). The contract end date is variable based on production and delivery of the requirement. There are significant challenges to overcome and the end date may not be a true reflection, setting unrealistic expectation for the public and in the market. This information is also being withheld on due to commercial sensitivity under Regulation 50(6)(b) and (c) as there is significant competition to develop and bring to the market a successful vaccine. Provision of the contract term may provide valuable information to competitors that may impact negotiations or future competition in the market.
Share this notice
Closing: 14 January 2021, 11:59pm